Company intelligence / Profile preview

CardioGard Medical

Or Yehuda, Central District, Israelfinder.startupnationcentral.org ↗

Ownership: Private
Development stage: Preclinical

Overview

The company’s main product, the CardioGard Emboli Protection Cannula, has received FDA 510(k) clearance. It combines a standard arterial cannula with a suction mechanism to capture and remove embolic debris during cardiopulmonary bypass procedures. This aims to reduce complications from emboli during heart surgeries. No published clinical trial results were found; regulatory approval suggests successful demonstration of safety and performance.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Not publicly disclosed

Beyond the preview

Go deeper on CardioGard Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardioGard Medical.

Explore the full profile